Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. by Chong, V

“…There are 4 anti-VEGF agents that are either approved or in common use in ophthalmology, namely pegaptanib (Macugen, Pfizer), ranibizumab (Lucentis, Novartis), aflibercept or VEGF Trap-Eye (EYLEA, Bayer) and bevacizumab (Avastin, Roche). …”

Microinvasive surgery in the treatment of retinal detachment associated with an optic disk pit: 2 cases report by S. V. Sdobnokova, N. A. Troitskaya, N. Yu. Malakyan

“…First was treated by intravitreal injection of Lucentis. Woman was treated by gas tamponade as a primary procedure. …”
Get full text

Signicef® (levoflaxacin 0.5%) eye drops in clinical practice by E. A. Spiridonov

“…Purpose: to evaluate the effect of levoflaxacin 0.5% eye drops/Signicef® (Promed Exports, India) for prevention of infectious complications following ocular traumas and intraocular surgery as well as infectious disorders treatment.Methods: In retrospective analysis were included 102 cases of different ophthalmic pathologies following intraocular surgery, i.e., phacoemulsification (27 cases), extracapsular cataract extraction (40 cases), intravitreal injection/IVt of Lucentis (23 cases), abscess/phlegmon drainage (3 cases). …”
Get full text

Future of anti-VEGF: biosimilars and biobetters by Monika Kapur, Suvansh Nirula, Mayuresh P. Naik

“…Abstract The advent of Anti- VEGFs like Lucentis (Ranibizumab), Eylea (Aflibercept) and off-label Avastin (Bevacizumab) have radically improved visual outcomes in patients of neovascular Age Related Macular Degeneration (nARMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). …”
Get full text

Multiple Intravitreal Ranibizumab Injections for Persistant Choroidal Neovascularization Associated with Presumed Ocular Histoplasmosis Syndrome by Turgut Yılmaz, Seyhan Dikci, Oğuzhan Genç, Kayhan Mutlu

“…We report a case with persistent CNV secondary to POHS in a middle-aged woman with moderate myopia and the clinical course of treatment with multiple intravitreal ranibizumab (Lucentis®, Novartis) injections.…”
Get full text

Natural and synthetic homoisoflavonoids and related compounds for the treatment of macular degeneration by Schwikkard, S., Hiles, J., Opara, Elizabeth, Whitmore, H., Corson, T., Mulholland, D.

“…Current treatments include the use of anti-VEGF agents such as Bevacizumab (Avastin) and Ranibizumab (Lucentis). Due to the cost of these treatments and the variable outcomes, the possibility of a small molecule treatment is very attractive. …”

Application and mechanism of anti-VEGF drugs in age-related macular degeneration by Dawei Song, Ping Liu, Kai Shang, YiBin Ma

“…Targeted VEGF drugs for neovascularization, such as Lucentis and Aflibercept, are the first-line drugs for AMD. …”
Get full text

Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab by Menke, Marcel N., Salam, Adzura, Framme, Carsten, Wolf, Sebastian

“…Background/Aims: To investigate the long-term effects of multiple intravitreal injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration. …”
Get full text
Get full text

Dry age-related macular degeneration - therapeutic possibilities and research directions by Alicja Zajdel

“…The three approved for ophthalmic indications are ranibizumab (Lucentis), aflibercept (Eylea), brolucisumab (Beovu) and off-label bevacizumab (Avastin). …”
Get full text

Incidence of endophthalmitis following intravitreal anti VEGF injections at a tertiary care hospital in Pakistan by Fiza Shaheen, Muhammad Amer Awan, Aiman Hafeez, Aqdus Haq, Ramsha Zainab, Admin

“…Total 7542 Anti-VEGF injections; 5976 (79.2%) Bevacizumab (Avastin), 1081 (14.3%) Ranibizumab (Patizra/ Lucentis) and 485 (6.4%) Aflibercept (Eylea) were administered to 2734 patients in a clean room in an office based setup during the 5 years i.e. …”
Get full text

Ranibizumab inhibits human tenon’s fibroblast proliferation via p21 dependent p53 mechanisms by Siti Munirah Md Noh, Siti Hamimah Sheikh Abdul Kadir, Sushil Vasudevan

“…In a trabeculectomy, number of clinical trials have shown the efficacy of ranibizumab in minimizing extracellular matrix accumulation at the filtering site. Ranibizumab (LucentisTM) is a drug that targets vascular endothelial growth factor (VEGF). …”
Get full text

Intravitreal Ranibizumab for Treatment of Posttraumatic Choroidal Neovascularization: a Case Report by A. N. Kulikov, A. Yu. Kuznetsova, N. A. Nekrash, D. S. Maltsev

“…A follow-up examination in August 2018 revealed an increase in CNV activity according to OCTA and fluorescence angiography (FAG), in connection with which intravitreal administration of ranibizumab (lucentis) was performed. Subsequently, the patient was under dynamic observation for one year. …”
Get full text

Clinical and functional evaluation of efficiency in the treatment of macular edema associated with thrombosis of the central retinal vein and its branches by T. G. Kamenskikh, Y. S. Batishcheva, E. V. Gileva, I. O. Kolbenev

“…Patients were divided into three groups, depending on the performed treatment: the group I (25 eyes) – intravitreal injections of ranibizumab (Lucentis), the group II (26 eyes) – intravitreal injections of aflibercept (Eilea), the group III (26 eyes) – intravitreal injections of Ozurdex. …”
Get full text

TACTICS OF TREATMENT FOR PATIENTS WITH RETINAL ARTERIAL MACRO-ANEURYSM by A. G. Shchuko, V. V. Bukina, T. N. Iureva, M. V. Akulenko, A. N. Zlobina

“…The positive dynamics was noted in 5 cases. Intravitreal Lucentis was injected to the patient of the group 4 as a first step, and barrage of macular area was made as the second step. …”
Get full text

Fabrication of core-shell nanoparticles for protein delivery by Koh, Weixiang

“…The active protein used for the treatment of AMD, Lucentis, was used as a model drug in the loading and release experiments in this study. …”
Get full text

Intravitreal Injection of Dexamethasone Implant and Ranibizumab in Cystoid Macular Edema in the Course of Irvine-Gass Syndrome by Vito Fenicia, Marco Balestrieri, Andrea Perdicchi, Maurizio Maurizi Enrici, Martina Delle Fave, Santi Maria Recupero

“…Conclusion: Treatment with dexamethasone implants (Ozurdex®) and ranibizumab injections (Lucentis®) induced a progressive reduction of our patient's CME after cataract surgery (Irvine-Gass syndrome) until a complete normal foveal thickness was restored and his visual function was improved despite the order of injections.…”
Get full text

Analysis of intravitreal using of anti vegf-medications for diseases of fundus accompanied by exudation and neovascularization by N. G. Zavgorodnya, I. A. Poplavska, S.L. Shevluk, D.V. Martynov

“…Pegaptanib ("Macugen") was used for the treatment of 35 patients (35 eyes), the rest (15 eyes) - ranibizumab ("Lucentis"). According to fluorescein angiography the subretinal neovascular membrane was in the stage of activity in all eyes. …”
Get full text

Combined modality therapy for exsudative form of age-related macular degeneration by М. V. Budzinskaya, I. V. Gurova, I. V. Schegoleva, V. B. Loschenov, S. А. Shevchik, S. G. Kuzjmin, G. N. Vorogtsov

“…Treatment outcomes in patients with age-related vascular degeneration due to formation of subretinal neovascular membrane (SNM) of two groups: photodynamic therapy (PDT) with Photosens alone (18 patients) and in combination with anti-VEGF therapy with Lucentis (20 patients). For both groups Photosens was administrated i.v. in single dose of 0.05 mg/kg. …”
Get full text

The Application of Structural Retinal Biomarkers to Evaluate the Effect of Intravitreal Ranibizumab and Dexamethasone Intravitreal Implant on Treatment of Diabetic Macular Edema by Ida Ceravolo, Giovanni William Oliverio, Angela Alibrandi, Ahsan Bhatti, Luigi Trombetta, Robert Rejdak, Mario Damiano Toro, Costantino John Trombetta

“…Methods: 156 treatment-naïve patients with DME were divided in two groups: 75 patients received 3 monthly intravitreal injections of ranibizumab 0.5 mg (Lucentis^®) (Group 1) and 81 patients received an intravitreal implant of dexamethasone 0.7 mg (Ozurdex^®) (Group 2). …”
Get full text

The Role of Steroids in the Management of Macular Edema from Retinal Vein Occlusion by M. V. Budzinskaya, A. V. Shelankova, A. A. Plukhova, N. M. Nuriyeva, A. S. Sorokin

“…For the treatment of macular edema were used an anti-VEGF agent — ranibizumab (Lucentis) 0.05 ml (0.5 mg) manufactured by Novartis (Switzerland) or glucocorticosteroid — dexamethasone implant for intravitreal injection of 0.7 mg (Ozurdex) manufactured by Allergan Pharmaceutical Ireland (Ireland). …”
Get full text